In contradiction to the two approved HPV vaccines that target approximately 70% of HPV strains, Dynavax Technologies is into developing a vaccine that provides immunity to nearly all cancer-causing strains of HPV.
Dynavax Technologies is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious diseases.
Dynavax Technologies’ lead product candidate Heplisav is an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines.
Heplisav is known to combine hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.